These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852 [TBL] [Abstract][Full Text] [Related]
4. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Baraf HS; Becker MA; Gutierrez-Urena SR; Treadwell EL; Vazquez-Mellado J; Rehrig CD; Ottery FD; Sundy JS; Yood RA Arthritis Res Ther; 2013 Sep; 15(5):R137. PubMed ID: 24286509 [TBL] [Abstract][Full Text] [Related]
5. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase. Mandell BF; Yeo AE; Lipsky PE Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229 [TBL] [Abstract][Full Text] [Related]
6. A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study. Botson JK; Tesser JRP; Bennett R; Kenney HM; Peloso PM; Obermeyer K; Song Y; LaMoreaux B; Zhao L; Xin Y; Chamberlain J; Ramanathan S; Weinblatt ME; Peterson J Arthritis Res Ther; 2022 Aug; 24(1):208. PubMed ID: 36008814 [TBL] [Abstract][Full Text] [Related]
7. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares. Mandell BF; Fields TR; Edwards NL; Yeo AE; Lipsky PE Clin Exp Rheumatol; 2021; 39(5):1085-1092. PubMed ID: 33427618 [TBL] [Abstract][Full Text] [Related]
8. Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels. Keenan RT; Yeo AE; Lipsky PE Clin Exp Rheumatol; 2022 May; 40(5):1006-1010. PubMed ID: 35238750 [TBL] [Abstract][Full Text] [Related]
12. Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial. Botson JK; Obermeyer K; LaMoreaux B; Zhao L; Weinblatt ME; Peterson J Arthritis Res Ther; 2022 Dec; 24(1):281. PubMed ID: 36575505 [TBL] [Abstract][Full Text] [Related]
13. A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. Botson JK; Saag K; Peterson J; Parikh N; Ong S; La D; LoCicero K; Obermeyer K; Xin Y; Chamberlain J; LaMoreaux B; Verma S; Sainati S; Grewal S; Majjhoo A; Tesser JRP; Weinblatt ME Arthritis Rheumatol; 2023 Feb; 75(2):293-304. PubMed ID: 36099211 [TBL] [Abstract][Full Text] [Related]
14. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z; Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308 [TBL] [Abstract][Full Text] [Related]
15. Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. Calabrese LH; Kavanaugh A; Yeo AE; Lipsky PE Arthritis Res Ther; 2017 Aug; 19(1):191. PubMed ID: 28818095 [TBL] [Abstract][Full Text] [Related]
16. Pegloticase for chronic gout. Anderson A; Singh JA Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008335. PubMed ID: 20238366 [TBL] [Abstract][Full Text] [Related]
17. Interventions for tophi in gout. Sriranganathan MK; Vinik O; Bombardier C; Edwards CJ Cochrane Database Syst Rev; 2014 Oct; (10):CD010069. PubMed ID: 25330136 [TBL] [Abstract][Full Text] [Related]
18. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. Strand V; Khanna D; Singh JA; Forsythe A; Edwards NL J Rheumatol; 2012 Jul; 39(7):1450-7. PubMed ID: 22660805 [TBL] [Abstract][Full Text] [Related]
19. Pegloticase: a novel agent for treatment-refractory gout. Shannon JA; Cole SW Ann Pharmacother; 2012 Mar; 46(3):368-76. PubMed ID: 22395256 [TBL] [Abstract][Full Text] [Related]
20. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout. Johnson RJ; Choi HK; Yeo AE; Lipsky PE Hypertension; 2019 Jul; 74(1):95-101. PubMed ID: 31079535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]